ACTON, Mass. / May 13, 2025 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, is proud to announce the publication of its 2024 Sustainability Report. This report underscores Insulet's unwavering commitment to sustainable practices and highlights significant achievements in environmental, social, and... Read More

Raising Full Year Revenue and Gross Margin Guidance ACTON, Mass. / May 08, 2025 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced financial results for the three months ended March 31, 2025. “Our first quarter results showcase the strong execution and dedication of the Insulet team, who has... Read More

Expects to Exceed First Quarter Revenue Guidance and Raise Full Year 2025 Guidance ACTON, Mass. / Apr 28, 2025 / Business Wire / Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced its Board of Directors has appointed Ashley McEvoy President and Chief Executive Officer and a member of the Board of... Read More

New Diabetes Canada Guidelines 1 recommend people with type 1 diabetes use an Automated Insulin Delivery System (AID) System for diabetes management Approximately 300,000 Canadians have type 1 diabetes, with the number of cases growing at an estimated 4.4% per year 2 The Omnipod 5 System is designed to be customer-centric and aims to deliver exceptional ease of use. It has demonstrated strong clinical results including lower... Read More

ACTON, Mass. / Apr 03, 2025 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the first quarter of 2025 on May 8, 2025, after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30... Read More

First randomized controlled trial to evaluate direct transition from multiple daily injections to automated insulin delivery in adults and children with type 1 diabetes who were not meeting glycemic targets with injections People using Omnipod 5 had significantly improved HbA1c levels (average reduction of -0.8%) compared with those using multiple daily injections with a continuous glucose monitor at the end of the... Read More

ACTON, Mass. / Mar 18, 2025 / Business Wire / Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, has priced a private placement of $450 million aggregate principal amount of senior unsecured notes due 2033 (the “Notes”). The Notes will bear interest at an annual rate of 6.50% and will mature on April 1, 2033, unless... Read More

ACTON, Mass. / Mar 18, 2025 / Business Wire / Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced its intention to offer, subject to market and other conditions, $450 million aggregate principal amount of senior unsecured notes due 2033 (the “Notes”) in a private placement. The Company intends to use the... Read More

The Omnipod 5 Automated Insulin Delivery System is now commercially available in Australia, launching soon in Belgium, Canada, and Switzerland. ACTON, Mass. / Mar 18, 2025 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced its revolutionary Omnipod 5 Automated Insulin Delivery (AID) System... Read More

ACTON, Mass. / Mar 18, 2025 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced the Company will present results from its multinational Randomized Controlled Trial to Demonstrate the Efficacy of Omnipod 5 Compared with Multiple Daily Injections for Treatment of Type 1 Diabetes (RADIANT). The... Read More

ACTON, Mass. / Mar 11, 2025 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, will host an Investor Day at the Company's global headquarters in Acton, Massachusetts on Thursday, June 5, 2025. Presentations will be led by Jim Hollingshead, President and CEO, members of the Executive Leadership Team, and... Read More

Represents 9th Consecutive Year of 20% or More Constant Currency 1 Revenue Growth; Annual Revenue Surpasses $2 Billion ACTON, Mass. / Feb 20, 2025 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced financial results for the three months and full year ended December 31, 2024. "We concluded an... Read More

The Omnipod 5 Automated Insulin Delivery System is now commercially available in Italy, Denmark, Finland, Norway, and Sweden with Abbott’s FreeStyle Libre 2 Plus and Dexcom G6 ACTON, Mass. / Jan 13, 2025 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced the Omnipod 5 Automated Insulin... Read More

ACTON, Mass. / Jan 10, 2025 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the fourth quarter and full year of 2024 on February 20, 2025, after the close of the financial markets. In connection with the release, management will host a conference... Read More

Jury awards $452M in damages ACTON, Mass. / Dec 04, 2024 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, announced that it has successfully defended its intellectual property against EOFlow Co., Ltd. (“EOFlow") in federal court. After a four-week trial in the U.S. District Court for the District of... Read More

ACTON, Mass. / Nov 20, 2024 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the Omnipod 5 Automated Insulin Delivery (AID) System is now compatible with Abbott’s FreeStyle Libre 2 Plus continuous glucose monitoring (CGM) sensor in the U.S. This makes Omnipod 5 the most connected tubeless... Read More

ACTON, Mass. / Nov 15, 2024 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced that management will present at three upcoming investor conferences (all Eastern Time): The 6 th Annual Wolfe Research Healthcare Conference in New York City on Wednesday, November 20, 2024 at 12:00 p.m. The Nasdaq 51 st... Read More

Raising Full Year Revenue and Margin Guidance ACTON, Mass. / Nov 07, 2024 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced financial results for the three months ended September 30, 2024. “We continue to achieve significant milestones and robust revenue growth," said Jim Hollingshead,... Read More

Key events feature the Nasdaq closing bell ceremony, a panel discussion hosted by the American Diabetes Association, the debut of a new podcast, and various employee initiatives to further raise awareness ACTON, Mass. / Nov 01, 2024 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced plans to... Read More

Insulet is the first and only company to offer a tubeless automated insulin delivery (AID) system with full control from a compatible iPhone or Android ™ phone Provides more choice and added convenience for Omnipod 5 users ACTON, Mass. / Oct 29, 2024 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today... Read More

SAN FRANCISCO , Oct. 10, 2024 /PRNewswire/ -- The Spoonful of Laughter campaign is a national initiative using comedy to educate about diabetes, counter harmful stereotypes and stigma, and amplify authentic, respectful, and empowering representations of people living with diabetes. The campaign is from the diaTribe Foundation , a nonprofit dedicated to diabetes education and advocacy, and a leader in the movement to end... Read More

ACTON, Mass. / Sep 30, 2024 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the third quarter of 2024 on November 7, 2024 after the close of the financial markets. In connection with the release, management will host a conference call that day at... Read More

Label expansion makes Omnipod 5 commercially available to 6 million people living with insulin-requiring type 2 diabetes Omnipod 5 is the first and only automated insulin delivery (AID) system indicated for both type 1 and type 2 diabetes ACTON, Mass. / Aug 26, 2024 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of... Read More

ACTON, Mass. / Aug 20, 2024 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced that management will present at three upcoming investor conferences (all Eastern Time): The 2024 Wells Fargo Healthcare Conference in Boston on Wednesday, September 4, 2024 at 9:30 a.m. The Morgan Stanley 22nd Annual Global... Read More

Global tubeless insulin pump technology leader officially commences manufacturing of Omnipod ® 5 Automated Insulin Delivery System at new facility, enabling continued worldwide customer growth ACTON, Mass. / Aug 14, 2024 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in... Read More

Raising Full Year Revenue, Gross Margin and Operating Margin Guidance ACTON, Mass. / Aug 08, 2024 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced financial results for the three months ended June 30, 2024. Second Quarter Financial Highlights: Second quarter 2024 revenue of $488.5 million,... Read More

Second Quarter Revenue Increased 23% Year-Over-Year Raising Full Year 2024 Total Omnipod Revenue Outlook ACTON, Mass. / Jul 26, 2024 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced certain preliminary revenue results for the three months ended June 30, 2024. The Company plans to report... Read More

ACTON, Mass. / Jul 08, 2024 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the second quarter of 2024 on August 8, 2024 after the close of the financial markets. In connection with the release, management will host a conference call that day at... Read More

Largest, longest, and most racially diverse study of automated insulin delivery (AID) conducted in people with type 2 diabetes to date ACTON, Mass. / Jun 21, 2024 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today shared positive results from its Omnipod 5 Automated Insulin Delivery System (Omnipod 5)... Read More

Following a successful limited market release, the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) is now fully available with Dexcom G6 and Abbott FreeStyle Libre 2 Plus in these countries ACTON, Mass. / Jun 20, 2024 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced that Omnipod 5,... Read More

Omnipod 5, the world’s first tubeless automated insulin delivery (AID) system integrated with Dexcom G6, is now available in France Full commercial launch of Omnipod 5 with Dexcom G7 integration has commenced in the U.S. Omnipod 5 App for iPhone begins limited market release in the U.S. ACTON, Mass. / Jun 20, 2024 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless... Read More

ACTON, Mass. / May 28, 2024 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced that management will present at the Jefferies Global Healthcare Conference in New York City on Thursday, June 6, 2024 at 9:00 a.m. (Eastern Time). To listen to the live audio webcast of the presentation, please visit... Read More

Raising Full Year Revenue and Operating Margin Guidance ACTON, Mass. / May 09, 2024 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced financial results for the three months ended March 31, 2024. First Quarter Financial Highlights: First quarter 2024 revenue of $441.7 million, up 23.3%, or... Read More

ACTON, Mass. / May 07, 2024 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today released its 2023 Sustainability Report , which describes key accomplishments in environmental, social, and governance (ESG) areas in 2023. The report outlines how the Company’s efforts to focus on sustainability through... Read More

ACTON, Mass. / Apr 03, 2024 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the first quarter of 2024 on May 9, 2024 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30... Read More

ACTON, Mass. / Mar 20, 2024 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced that Ana Maria Chadwick has been appointed Executive Vice President, Chief Financial Officer and Treasurer, effective April 22, 2024. Today’s announcement concludes an extensive search process conducted by the... Read More

ACTON, Mass. / Mar 08, 2024 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today presented positive results from its first randomized controlled trial (RCT) showing improved glycemic and patient-reported outcomes in type 1 diabetes with the Omnipod 5 Automated Insulin Delivery System (Omnipod 5). The... Read More

Conducted in the United States and France, the OP5-003 Trial is the first Omnipod 5 study to include international participants. The OP5-003 Trial Presentation and Insulet Symposium will convey the importance of automated insulin delivery (AID) technology as Standard of Care. An expanded set of Omnipod 5 Real-World Evidence with more than 100,000 users will also be presented, showing positive outcomes and insights to guide... Read More

Represents 8th Consecutive Year of 20% or More Constant Currency Revenue Growth ACTON, Mass. / Feb 22, 2024 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced financial results for the three months and full year ended December 31, 2023. Full Year Financial Highlights: Full year 2023 revenue... Read More

ACTON, Mass. / Feb 13, 2024 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced that management will present at The Raymond James & Associates 45 th Annual Institutional Investors Conference in Orlando on Tuesday, March 5, 2024 at 11:35 a.m. (Eastern Time). To listen to the live audio webcast of the... Read More

Omnipod 5 is the world’s first tubeless automated insulin delivery system to achieve CE mark approval with multiple continuous glucose monitoring (CGM) sensor brands. Latest Omnipod 5 integration is expected to be available in the United Kingdom and Netherlands in the first half of 2024, with additional markets to follow.... Read More

Flavia Pease and Timothy Stonesifer to join Board of Directors Shacey Petrovic and Corinne Nevinny to retire from the Board at the Company’s 2024 Annual Meeting ACTON, Mass. / Jan 18, 2024 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the following appointments to the Company’s Board of... Read More

ACTON, Mass. / Jan 11, 2024 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced plans to release its financial results for the fourth quarter and full year of 2023 on February 22, 2024 after the close of the financial markets. In connection with the release, management will host a conference... Read More

ACTON, Mass. / Nov 28, 2023 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced that management will present at two upcoming investor conferences (all Eastern Time): The Nasdaq 29 th Investor Conference in London on Tuesday, December 5, 2023 at 10:00 a.m. The J.P. Morgan Annual Healthcare Conference in San... Read More

Raised Full Year Revenue Guidance to a Range of 26% to 27%, including Total Omnipod of 29% to 30% ACTON, Mass. / Nov 02, 2023 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced financial results for the three months ended September 30, 2023. Third Quarter Financial Highlights: Third quarter... Read More

Highlights Include Pledge to End Diabetes Stigma, Nasdaq Closing Bell Ceremony, and Educational Events ACTON, Mass. / Nov 01, 2023 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced a series of initiatives in recognition of National Diabetes Awareness Month and World Diabetes Day. “Our... Read More

ACTON, Mass. / Oct 23, 2023 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced it has received FDA 510(k) clearance for the Omnipod 5 App for iPhone, making Insulet the first and only company to offer a tubeless automated insulin delivery (AID) system with full control from a compatible... Read More

Reaffirms Guidance for Third Quarter and Fiscal Year 2023 ACTON, Mass. / Oct 03, 2023 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced that Wayde McMillan has decided to step down from his role as Executive Vice President, Chief Financial Officer and Treasurer, effective October 20, 2023.... Read More

Key learnings on Omnipod 5 and other data to be presented at the 59 th Annual Meeting of the European Association for the Study of Diabetes (EASD) ACTON, Mass. / Oct 02, 2023 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced its schedule of events and presentations at EASD 2023, taking... Read More

ACTON, Mass. / Sep 28, 2023 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced plans to release its financial results for the third quarter of 2023 on November 2, 2023 after the close of the financial markets. In connection with the release, management will host a conference call that day at... Read More

ACTON, Mass. / Aug 28, 2023 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced the commercial launch of its Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for individuals aged two years and older with type 1 diabetes (T1D) in its third market, Germany. Omnipod 5 is also available in... Read More

ACTON, Mass. / Aug 24, 2023 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced that management will present at three upcoming investor conferences (all Eastern Time): The 2023 Wells Fargo Healthcare Conference on Thursday, September 7, 2023 at 9:30 a.m. The Baird 2023 Global Healthcare Conference on... Read More

ACTON, Mass. / Aug 08, 2023 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced financial results for the three months ended June 30, 2023. Second Quarter Financial Highlights: Second quarter 2023 revenue of $396.5 million, up 32.4%, or 32.2% in constant currency 1 , compared to $299.4... Read More

ACTON, Mass. / Jul 05, 2023 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the second quarter of 2023 on August 8, 2023 after the close of the financial markets. In connection with the release, management will host a conference call that day at... Read More

Exciting lineup of events showcasing real-world evidence of improved outcomes and what the future holds for Omnipod’s tubeless automated insulin delivery ACTON, Mass. / Jun 22, 2023 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced an exciting lineup of events and product developments that... Read More

ACTON, Mass. / Jun 20, 2023 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced the commercial launch of its Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for individuals aged two... Read More

Structured to Accelerate Innovation and Commercialization Priorities Creates New Roles to Oversee Product & End-to-End Customer Experience and Technology ACTON, Mass. / May 04, 2023 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced its new organizational structure designed to accelerate... Read More

ACTON, Mass. / May 04, 2023 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced financial results for the three months ended March 31, 2023. First Quarter Financial Highlights: First quarter 2023 revenue of $358.1 million, up 21.2%, or 23.3% in constant currency 1 , compared to $295.4 million... Read More

ACTON, Mass. / May 02, 2023 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today released its 2022 Sustainability Report highlighting accomplishments in environmental, social, and governance (ESG) across its global markets. The report details the Company’s efforts to optimize value while revolutionizing... Read More

ACTON, Mass. / Apr 25, 2023 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced the FDA clearance of its latest innovation, Omnipod GO™, an insulin delivery device cleared for use for people... Read More

ACTON, Mass. / Mar 30, 2023 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the first quarter of 2023 on May 4, 2023 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30... Read More

NEW YORK , March 10, 2023 /PRNewswire/ -- Insulet Corp. (NASD:PODD) will replace SVB Financial Group (NASD:SIVB) in the S&P 500 effective prior to the opening of trading on Wednesday, March 15 . The Federal Deposit Insurance Corporation (FDIC) announced that it has taken SVB Financial Group into FDIC Receivership and therefore SVB Financial Group is no longer eligible for inclusion. Following is a summary of the changes that... Read More

Represents 7th Consecutive Year of 20% or More Constant Currency Revenue Growth Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced financial results for the three months and full year ended December 31, 2022. Full Year Financial Highlights: Full year 2022 revenue of $1.3 billion, up 18.8%, or 22.5% in... Read More

ACTON, Mass. / Feb 21, 2023 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced the presentation of new real-world evidence related to the Omnipod ® 5 Automated Insulin Delivery System at the 16 th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) taking place... Read More

ACTON, Mass. / Feb 14, 2023 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced it has acquired the assets of Automated Glucose Control LLC (AGC), a company in Palo Alto, California focused on developing and commercializing best in class automated insulin delivery technology. AGC and Insulet... Read More

ACTON, Mass. / Feb 14, 2023 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced that management will present at two upcoming investor conferences: The Raymond James & Associates 44 th Annual Institutional Investors Conference in Orlando, FL on Tuesday, March 7, 2023 at 9:15 a.m. (Eastern Time) The Cowen 43... Read More

ACTON, Mass. & MILPITAS, Calif. / Feb 13, 2023 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, and Bigfoot Biomedical (Bigfoot), a leader in developing intelligent connected injection support systems, today announced Insulet has acquired assets related to Bigfoot’s pump-based automated insulin delivery (AID)... Read More

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced plans to release its financial results for the fourth quarter and full year of 2022 on February 23, 2023 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The... Read More